5T4-modified vaccinia Ankara: Progress in tumor-associated antigen-based immunotherapy

Expert Opinion on Biological Therapy

Volumn 10, Issue 2, 2010, Pages 281-287

  Amato, Robert J ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

5T4; Cancer; Immunotherapy; Tumor associated antigen; Vaccinia Ankara

Indexed keywords

ALPHA2B INTERFERON; DENILEUKIN DIFTITOX; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; OXALIPLATIN; PLACEBO; SUNITINIB;

ANTIBODY TITER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELLULAR IMMUNITY; CLEAR CELL CARCINOMA; CLINICAL TRIAL; COLORECTAL CANCER; DRUG DOSE ESCALATION; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EXPERIMENTAL NEOPLASM; HUMAN; IMMUNE RESPONSE; KIDNEY CARCINOMA; LOW DRUG DOSE; METASTASIS; MONOTHERAPY; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; SURVIVAL RATE; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CANCER VACCINES; CLINICAL TRIALS, PHASE II AS TOPIC; COLORECTAL NEOPLASMS; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; NEOPLASMS; PROSTATIC NEOPLASMS; VACCINIA; VACCINIA VIRUS;

MURINAE;

EID: 76149122520     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590903586213     Document Type: Review

References (29)

1. Harrop R, Ryan M. Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated. Cancer Immunol Immunother 2006;55(9):1081-1090
2. Harrop R, Connolly NB, Redchenko I, et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res 2006;12(11):3416-3424
3. Harrop R, Drury N, Shingler W, et al. Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin Cancer Res 2007;13(15 Pt 1):4487-4494
4. Harrop R, Hawkins RE, Anthoney A, et al. An open label phase II study of modified vaccinia ankara (MVA) expressing the tumor antigen 5T4 given in conjunction with chemotherapy: safety and immunogenicity before, during and after chemotherapy. 2005 ASCO Annual Meeting Proceedings. J Clin Oncol 2005;23(16S):2578
5. Dangoor A, Burt D, Harrop R, et al. A vaccinia-based vaccine (TroVax) targeting the oncofetal antigen 5T4 administered before and after surgical resection of colorectal cancer liver metastases: phase II trial. 2006 ASCO Annual Meeting Proceedings. J Clin Oncol 2006;24(18S):2574
6. Kaufman HL, Deraffele G, Mitcham J, et al. A phase I clinical trial of MVA expressing 5T4 and high-dose interleukin-2 (IL-2) for metastatic renal cell carcinoma. 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006;24(18S):12500
7. Amato R, Shingler W, Naylor S, et al. Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial. Clin Cancer Res 2008;14(22):7504-7510
8. Amato R, Shingler W, Goonewardena M, et al. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial. J Immunother 2009;32(7):765-772
9. Hawkins R, Harrop R, Naylor S, et al. TRIST: a randomised, double blind, placebo controlled phase III study of MVA-5T4 in metastatic renal cancer patients. Eur J Cancer Suppl 2009;7(3):11
10. Amato R, Drury N, Naylor S, et al. Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial. J Immunother 2008;31(6):577-585
11. Hole N, Stern PL. A 72 kD trophoblast glycoprotein defined by a monoclonal antibody. Br J Cancer 1988;57:237-246
12. Southall P, Boxer G, Bagshaw K, et al. Immunological distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer 1990;61:89-95
13. Starzynska T, Marsh P, Schofield P, et al. Prognostic significance of 5T4 oncofoetal antigen expression in colorectal carcinoma. Br J Cancer 1994;69:899-902
14. Griffiths RW, Gilham DE, Dangoor A, et al. Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy. Br J Cancer 2005;93(6):670-677
15. Barrow KM, Ward CM, Rutter J, et al. Embryonic expression of murine 5T4 oncofoetal antigen is associated with morphogenetic events at implantation and in developing epithelia. Dev Dyn 2005;233(4):1535-1545
16. Carsberg C, Myers KA, Stern PL. Metastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in ephithelial cells. Int J Cancer 1996;68(1):84-92
17. Carroll MW, Restifo NP. Poxviruses as vectors for cancer immunotherapy. In: Stern PL, Beverley PCL, Carroll MW, editors, Cancer vaccines and immunotherapy. Cambridge University Press, Cambridge, UK; 2000. p. 47-65
18. Sutter G, Moss B. Non-replicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci USA 1992;89:10847-10851
19. Rochlitz C, Figlin R, Squiban P, et al. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med 2003;5(8):690-699
20. Eder J, Kantoff P, Roper K, et al. A Phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 2000;6(5):1632-1638
21. Marshall J, Hoyer R, Toomey M, et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000;18(23):3964-3973
22. Marlow S. Trovax Gene Therapy Vaccine Product: Investigator's Brochure Oxford, Oxford Biomedica, 2006
23. Redchenko I, Harrop R, Ryan MG, et al. Identification of a major histocompatibility complex class I-restricted epitope in the tumour-associated antigen, 5T4. Immunology 2006;118:50-57
24. Motzer R, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530-2540
25. Yang J, Sherry R, Steinberg S, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21:3127-3132
26. Tannock I, De Wit R, Berry W, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-1512
27. Petrylak D, Tangen C, Hussain M, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351(15):1513-1520
28. Rini B, Bok R, Small E. Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer. J Clin Oncol 2003;21(1):99-105
29. Small E, Reese D, Um B, et al. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res 1999;5:1738-1744